Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1370–1375. doi: 10.1128/aac.35.7.1370

In vitro activity of YM133, a new semisynthesized macrolide.

T Terasawa 1, M Watanabe 1, T Okubo 1, S Mitsuhashi 1
PMCID: PMC245174  PMID: 1929295

Abstract

YM133, the 4"-O-(4-methoxyphenyl)acetyltylosin, is a new macrolide. The in vitro activity of YM133 was compared with those of erythromycin, josamycin, and rokitamycin by an agar dilution method. YM133 inhibited 90% of the tested isolates of Streptococcus pneumoniae, Legionella spp., and anaerobic bacteria at less than or equal to 1.56 micrograms/ml. The drug inhibited 90% of erythromycin-resistant staphylococci and Streptococcus pyogenes at less than or equal to 50 micrograms/ml. YM133 showed activity against erythromycin-, josamycin-, and rokitamycin-resistant (MIC greater than or equal to 100 micrograms/ml) strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp. Enterococci were less susceptible to other YM133-like macrolides. Unlike other macrolides, YM133 showed killing activity, and the MBC/MIC ratios of YM133 for several strains were 1:32, whereas those of erythromycin were 4:1,024. In a time-kill curve study, the reduction of viable cells started within 2 h after the addition of YM133.

Full text

PDF
1370

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chin N. X., Neu N. M., Labthavikul P., Saha G., Neu H. C. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1987 Mar;31(3):463–466. doi: 10.1128/aac.31.3.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fernandes P. B., Bailer R., Swanson R., Hanson C. W., McDonald E., Ramer N., Hardy D., Shipkowitz N., Bower R. R., Gade E. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986 Dec;30(6):865–873. doi: 10.1128/aac.30.6.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989 Sep;33(9):1413–1418. doi: 10.1128/aac.33.9.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kiyoshima K., Sakamoto M., Ishikura T., Fukagawa Y., Yoshioka T., Naganawa H., Sawa T., Takeuchi T. Application of dibutyltin oxide method to regioselective acylation and alkylation of tylosin at C-4''. Chem Pharm Bull (Tokyo) 1989 Apr;37(4):861–865. doi: 10.1248/cpb.37.861. [DOI] [PubMed] [Google Scholar]
  7. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Okamoto R., Nomura H., Tsuchiya M., Tsunekawa H., Fukumoto T., Inui T., Sawa T., Takeuchi T., Umezawa H. The activity of 4''-acylated tylosin derivatives against macrolide-resistant gram-positive bacteria. J Antibiot (Tokyo) 1979 May;32(5):542–544. doi: 10.7164/antibiotics.32.542. [DOI] [PubMed] [Google Scholar]
  9. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Takeuchi T., Sawa T., Naganawa H., Hamada M., Umezawa H., Yoshioka T., Kiyoshima K., Iguchi H., Sakamoto M., Shimauchi Y. 4''-O-(4-methoxyphenyl)-acetyltylosin, a new macrolide derivative of therapeutic importance. J Antibiot (Tokyo) 1987 Sep;40(9):1358–1360. doi: 10.7164/antibiotics.40.1358. [DOI] [PubMed] [Google Scholar]
  11. Tamura A., Okamoto R., Yoshida T., Yamamoto H., Kondo S., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1988 Sep;32(9):1421–1426. doi: 10.1128/aac.32.9.1421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Taylor P. C., Schoenknecht F. D., Sherris J. C., Linner E. C. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob Agents Chemother. 1983 Jan;23(1):142–150. doi: 10.1128/aac.23.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tsuchiya M., Hamada M., Takeuchi T., Umezawa H., Yamamoto K., Tanaka H., Kiyoshima K., Mori S., Okamoto R. Studies of tylosin derivatives effective against macrolide-resistant strains: synthesis and structure-activity relationships. J Antibiot (Tokyo) 1982 Jun;35(6):661–672. doi: 10.7164/antibiotics.35.661. [DOI] [PubMed] [Google Scholar]
  14. Watanabe M., Inoue M., Mitsuhashi S. In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance. Antimicrob Agents Chemother. 1989 Nov;33(11):1837–1840. doi: 10.1128/aac.33.11.1837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yoshioka T., Kiyoshima K., Maeda M., Sakamoto M., Ishikura T., Fukagawa Y., Sawa T., Hamada M., Naganawa H., Takeuchi T. Synthesis and structure-activity studies of new 4''-O-acyltylosin derivatives of therapeutic interest. J Antibiot (Tokyo) 1988 Nov;41(11):1617–1628. doi: 10.7164/antibiotics.41.1617. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES